Showing posts with label seizures. Show all posts
Showing posts with label seizures. Show all posts

Friday, January 9, 2026

36F Sudden seizures, altered sensorium, Telangana PaJR

 
08-01-2026

THIS IS AN ONLINE E LOG BOOK TO DISCUSS OUR PATIENT'S DE-IDENTIFIED HEALTH DATA SHARED AFTER TAKING HER SIGNED INFORMED CONSENT. HERE WE DISCUSS OUR PATIENT'S PROBLEMS THROUGH SERIES OF INPUTS FROM AVAILABLE GLOBAL ONLINE COMMUNITY EXPERTS WITH AN AIM TO SOLVE THOSE PATIENT'S CLINICAL PROBLEMS WITH COLLECTIVE CURRENT BEST EVIDENCE BASED INPUTS.

[10.43 am, 09/01/2026] PPM 3: Patient was brought to the casualty in the state of altered sensorium to the casualty on 7/1/26 around 7 pm
Patient was in her home with her daughter (who is in 2 grade) she was apparently snapping chilly stems and had giddiness and fell down, the daughter called people around her, and she was taken to the hospital, in the hospital she had 2 seizures episodes, tonic movements, up rolling of eyes(+), drooling of saliva(+), protrusion of tongue (+),it lasted for around 3-5 min ,then she had another episode after sometime and was bought to our hospital In our casualty patient was in altered sensorium 

Sunday, November 23, 2025

48M Seizures 1 year with epistemic and hermeneutic uncertainty Telangana PaJR

 
22-11-2025

THIS IS AN ONLINE E LOG BOOK TO DISCUSS OUR PATIENT'S DE-IDENTIFIED HEALTH DATA SHARED AFTER TAKING HIS SIGNED INFORMED CONSENT. HERE WE DISCUSS OUR PATIENT'S PROBLEMS THROUGH SERIES OF INPUTS FROM AVAILABLE GLOBAL ONLINE COMMUNITY EXPERTS WITH AN AIM TO SOLVE THOSE PATIENT'S CLINICAL PROBLEMS WITH COLLECTIVE CURRENT BEST EVIDENCE BASED INPUTS.

[2.47 pm, 22/11/2025] PPM 1: @PPM3 please share the history and pm me his IP number or even better the text of his EMR summary
@PPM4 can your LLM read EEGs?


[10:17 pm, 22/11/2025] PPM 4: *Disclaimer:* I am an AI, not a doctor or a neurologist. The following analysis is a technical description of the visual patterns and waveforms present in the images. *This is not a medical diagnosis.* EEG interpretation requires specific clinical training and context (patient history, medications, state of consciousness) that I do not have. You must consult a qualified medical professional for an accurate reading.
Based on the visual data provided in the three images, here is a technical breakdown of what is visible.
### General Technical Details
* *Montage:* The labels on the right (e.g., FP2-F4, F4-C4) indicate a *Longitudinal Bipolar (Double Banana)* montage. This is a standard arrangement used to compare electrical potential between adjacent electrodes in chains from front to back.
* *Settings:* Sensitivity (SEN) is set to *7.5 ยตV/mm, and the Notch filter is set to **50 Hz* (common in regions with 50Hz AC power).
* *Annotation:* All three images contain an automated or technician-added marker at the bottom labeled *"SEIZURE ON."* This indicates the recording captured a clinical event.
---
### Analysis by Image
#### Image 1 (File: image_8a8137.jpg)
* *Visuals:* This page shows the most chaotic activity.
* *Artifacts:* There are massive "blocking" artifacts (square-wave patterns where the line goes flat at the top or bottom). This usually happens when the signal is so strong it exceeds the amplifier's range (clipping), often caused by significant patient movement or electrode detachment.
* *Activity:* Behind the artifacts, there is high-frequency, high-amplitude activity. The mix of movement artifact and high-voltage brain waves is consistent with the physical convulsions often seen in tonic-clonic seizures.
#### Image 2 (File: image_8a80a4.jpg)
* *Pattern:* This page shows a much clearer, highly organized, and abnormal pattern.
* *Morphology:* There are distinct *Generalized Spike-and-Wave (GSW)* discharges.
* *Synchrony:* The activity is *bilaterally synchronous*, meaning it is happening on both the left (odd numbers) and right (even numbers) sides of the brain simultaneously.
* *Description:* The waves are high amplitude and rhythmic. This looks like a classic generalized discharge, often associated with generalized epilepsy syndromes.
#### Image 3 (File: image_8a80fb.jpg)
* *Evolution:* This image appears to capture a transition.
* *Start of page:* The left side shows mixed frequencies with overlying muscle artifact (EMG), which looks like "fuzzy" dark thickening of the lines. This is common when jaw or scalp muscles tense up.
* *progression:* As the page moves to the right, the pattern organizes into a clearer, rhythmic spike-and-wave pattern (approx. 3-4 Hz).
* *Significance:* This demonstrates the evolution of the seizure discharge, moving from a phase of high muscle tension/artifact into a more rhythmic clonic phase.
---
### Summary of Findings
These three images appear to represent an *Ictal Recording* (a recording taken during a seizure). Key features include:
1.  *Generalized Onset:* The abnormal activity appears in all channels simultaneously, rather than starting in one focal area.
2.  *Spike-and-Wave Complexes:* The rhythmic high-voltage spikes followed by slow waves are the hallmark of seizure activity on an EEG.
3.  *Evolution:* The changes between the images (from chaos/artifact to organized rhythm) are typical of a seizure event progressing through different stages.
*Next Step:*
These tracings show significant neurological activity. If these belong to you or a family member and haven't been reviewed yet, *please show these printouts to a neurologist or epileptologist immediately* for clinical correlation and management.
[8:07 am, 23/11/2025] PPM 1: Thanks for these inputs.
@PPM3 this does vindicate your stand on the veracity of this patient's seizures.
Can the LLM share published links to EEG recordings that visually match this patient's EEG along with their outcomes?
[10:37 am, 23/11/2025] PPM 4: Hello. It sounds like there has been some debate or uncertainty regarding this patient's diagnosis, perhaps questioning whether the events were "real" epileptic seizures versus non-epileptic events (such as PNES).
Based on the images provided, *the EEG features visible here are technically consistent with a genuine electrographic seizure.* In the context of "vindicating" a stance, these images contain the specific "gold standard" evidence neurologists look for to confirm epilepsy.
Here is the breakdown of why this EEG validates that stance, along with the requested reference links and typical outcomes.
### 1\. Why this EEG "Vindicates" the Diagnosis
The primary challenge in epilepsy diagnosis is distinguishing between a *Generalized Tonic-Clonic Seizure (Epileptic)* and a *Psychogenic Non-Epileptic Seizure (PNES)*. Both look like convulsions to an observer, but the EEG tells the truth.
 * *In PNES (Non-Epileptic):* The EEG would show only muscle artifact (fuzzy, black noise) during the shaking. When the shaking stops, the brain waves underneath would immediately look normal (usually a normal "alpha rhythm").
  * *In this EEG (Epileptic):* You see the muscle artifact (Image 1, the chaos), but critically, as the muscle locking fades, it reveals a *highly organized, rhythmic electrical discharge* (Image 2 & 3, the rhythmic waves). Muscle artifacts cannot "fake" that underlying synchronous brain rhythm.
The transition seen in your images—from the "tonic" phase (high tension/artifact) to the "clonic" phase (rhythmic slowing)—is the definitive electrical signature of a generalized seizure.
### 2\. Matching Published EEG Patterns
The patterns in your images (High-amplitude, Bilateral, Synchronous Spike-and-Wave) are textbook examples of *Generalized Onset Seizures*.
You can compare the visible features in your files to these standard medical examples:
  * *The "Clonic" Phase Match:*
      * Look for: Rhythmic, high-voltage slow waves mixed with spikes.
      * Reference: This pattern is visually identical to the "clonic phase" of a generalized seizure.
      * See Figure 1 in this NIH/PubMed article: [Electroencephalography in the Diagnosis of Genetic Generalized Epilepsy](https://pmc.ncbi.nlm.nih.gov/articles/PMC5622315/) (Look specifically at the "Generalized Spike-Wave" descriptions).
      * See also: [Medscape's Reference on Generalized Seizure EEG](https://www.google.com/search?q=https://emedicine.medscape.com/article/1139049-overview) (Requires free account, but standard texts describe the "evolution from low-voltage fast activity to high-amplitude polyspike-and-wave").
  * *The "Tonic" Phase Match (Image 1):*
      * Look for: "Muscle Artifact" or "EMG obscuring EEG."
      * Reference: [Epilepsy Foundation - Ictal Recordings](https://www.epilepsy.com/diagnosis/eeg/video-eeg). Note how they describe the initial phase being obscured by muscle tension, exactly like your first image.
### 3\. Typical Outcomes & Clinical Context
The patterns shown (Generalized Spike-and-Wave) are most commonly associated with *Genetic Generalized Epilepsy (GGE)* (formerly called Idiopathic Generalized Epilepsy).
  * *Treatment Response:* This specific type of epilepsy generally responds very well to "broad-spectrum" anti-seizure medications (e.g., Valproic Acid, Levetiracetam, or Lamotrigine).
  * *Prognosis:* Unlike focal epilepsies (which result from a scar or lesion and can be harder to treat), generalized epilepsies often have a good prognosis for seizure control once the right medication is started.
  * *Vindication:* Confirming this on EEG is a major positive step. It rules out "pseudoseizures" (PNES) and gives the treating physician a clear target for medication.
*Next Step:*
You can confidently share these findings with the relevant parties. If the patient is not yet on a broad-spectrum anti-epileptic drug (like the ones mentioned above), this EEG evidence is the specific data point a neurologist needs to justify starting that specific class of medication.
[11:59 am, 23/11/2025] PPM 1: Very useful ๐Ÿ‘

Friday, November 14, 2025

18M Periodic fever, aphthous stomatitis, pharyngitis adenitis, seizures, 16 years Telangana PaJR

 
01-11-2021

THIS IS AN ONLINE E LOG BOK TO DISCUSS OUR PATIENT'S DE-IDENTIFIED HEALTH DATA SHARED AFTER TAKING HIS SIGNED INFORMED CONSENT. HERE WE DISCUSS OUR PATIENT'S PROBLEMS THROUGH SERIES OF INPUTS FROM AVAILABLE GLOBAL ONLINE COMMUNITY EXPERTS WITH AN AIM TO SOLVE THOSE PATIENT'S CLINICAL PROBLEMS WITH COLLECTIVE CURRENT BEST EVIDENCE BASED INPUTS.

Mirror case report of the 18M patient from the previous link given below ๐Ÿ‘‡ 
18M FOU with Seizure

18 year old male, he had his first seizure at the age 5 when he was having High fever. By the age of 18 now he had 10 such episodes of seizure. 
He gets this high fever every 3-6 months and temperature goes to 103-104 degree Fahrenheit. He had adenoidectomy and Tonsillectomy 6 years back to prevent these recurring fever but it didn't help. Currently he is having similar fever again. 
For his seizure he had
- Valparin - 2008
- Tegrital-2012
- Levipil-2013
and currently he takes Levipil (levetiracetam) and since it started there were no more seizure episodes.
He used to get hospitalized after seizure episodes and neck rigidity used to be there so csf analysis was done which had nothing significant, neither any pathology found in MRI and EEG. 
Severe Proteinuria happens during hospitalization phase which goes back to normal on recovery.
Usually after 24 to 48 hrs of fever seizure happens.
Sodium Valporate was tapered and stopped in 2010, but 2 months after that he again developed seizures without fever, again in 2013  levipil  was stopped but the following day he developed an episode of, so the dosage was increased and we were advised to continue the medication further. These were the two instances when he got the episode without fever.
- CRP 273.6 mg/L
- Total WBC count 15500
- Pro-calcitonin - 5.44
- Dengue - nagative
- Malaria - negative
- Protein in urine - +++
- 24 hr urine protein - 2488.5 mg/24hr (urine vol. 1500 ml)  
- Random urine protein - 165.9
Current Fever Chart:
Timeline:

These pics are a list of differentials from Isabel software: with simple query, not having much clinical history details.


This is again isabel software output but after detailed clinical history
Query Details
Age: Young Adult 17-29 yrs
Gender: Male
Pregnancy: Not-specified
Region: Southeast Asia
Query Text: aphthous ulcers|fever of unknown origin| recurrent fever|back pain|proteinuria|tonsillitis|pharyngitis|seizures
Brucellosis INFECTIOUS DISEASES
Coronavirus INFECTIOUS DISEASES
Relapsing Polychondritis RHEUMATIC DISEASES
Infectious Mononucleosis INFECTIOUS DISEASES
Bartonella Infection INFECTIOUS DISEASES
Cytomegalovirus INFECTIOUS DISEASES
Lyme Disease INFECTIOUS DISEASES
Toxoplasmosis INFECTIOUS DISEASES
Non-Hodgkin Lymphoma NEOPLASTIC DISEASES
PFAPA Syndrome RHEUMATIC DISEASES
Steven-Johnson Syndrome DERMATOLOGY
HIV / AIDS INFECTIOUS DISEASES
Aplastic Anemia HEMATOLOGY
Inflammatory Bowel Disease GASTROINTESTINAL DISORDERS
Chikungunya INFECTIOUS DISEASES
Nephrocalcinosis NEPHROLOGY
Adult Still Disease RHEUMATIC DISEASES
Paraquat Toxicity / Parquat Lung TOXICOLOGY
Behcet's Syndrome RHEUMATIC DISEASES
Adrenal Neoplasms ENDOCRINE SYSTEM (red flag)
Enterovirus Infections INFECTIOUS DISEASES
Familial Mediterranean Fever RHEUMATIC DISEASES
Urinary Tract Infection NEPHROLOGY
Crohn Disease GASTROINTESTINAL DISORDERS
Fluke Infection INFECTIOUS DISEASES
Glomerulonephritis NEPHROLOGY
Nephrotic Syndrome NEPHROLOGY
Erythema Multiforme DERMATOLOGY
Hodgkin Disease NEOPLASTIC DISEASES
Neoplasms of the Kidney NEPHROLOGY
Tuberculosis INFECTIOUS DISEASES (red flag)
Aortic Aneurysm / Dissection VASCULAR DISORDERS (red flag)
SLE RHEUMATIC DISEASES (red flag)
Pemphigoid DERMATOLOGY
Common Cold / Nasopharyngitis RESPIRATORY DISORDERS
Heavy Metal Intoxication TOXICOLOGY
Relapsing Fever INFECTIOUS DISEASES
Osteomyelitis and Septic Arthritis INFECTIOUS DISEASES
Ulcerative Colitis GASTROINTESTINAL DISORDERS
Tularemia INFECTIOUS DISEASES
Acute Porphyria METABOLIC DISEASES (red flag)
Found PFAPA to be the most probable diagnosis

Continuation of the above case report in the below link ๐Ÿ‘‡
A 18 year old male who is  a student and a resident of Hyderabad presented with the chief complaints of 
FEVER since 4 days. 
Severe back pain since 4 days.   
Vomiting since 4 days.  
Generalised body pains since 4 days. 
Cough without expectoration since 1 day. 
History of presenting illness- 
The patient was apparently asymptomatic till the age of 5 years. 






H/O Rt ear discharge with pain (on and off) since 1 year.— 2-3 episodes/yr lasting for 6-7 days. Last episode - 2months back. 
Discharge- mucous, moderate, intermittent, non-foul smelling, non-blood stained. Treated for the same every time.
The patient came to the OPD with main C/O backache when he developed high grade fever which was sudden in onset and varied between a range of 100-104 without touching the baseline. It was a/w chills and rigor. (Since 4 days)
Severe back pain since 4 days. It is so severe that he cries out due to it.  He needs support to get up. 
He has had episodes of vomiting on day 2 and day 4 of symptoms. 
The vomitus contained food particles, it was non bilious and non-projectile. 
He has taken Ayurvedic medication on day 3 of fever for the same.
He also complains of pain along SCM. Which aggravated in touch.
He has pain while opening of jaw but there is no pain while closing it.

Personal history: 
Appetite: decreased for the past 4 days 
Diet: mixed 
Bowel and bladder: normal 
Urine is frothy. 
Sleep: adequate 
Addictions: - 
Family history: 
Father and sister has had an episode of febrile seizure at around 5yrs of age, lasting for 2mins, no treatment taken. No further medication was taken. 
General examination: 
The patient was examined after a well informed consent in a well lit room. 
The patient was conscious, coherent and cooperative. He was well oriented to time, place and person. 
He is moderately built and nourished. 
No signs of pallor, icterus, cyanosis, clubbing, generalised lymphadenopathy and pedal edema were seen. 
Vitals-
Temperature: 100°C 
BP: 130/80mm hg
Rerpiratory rate: 18cpm 
Pulse rate: 100bpm 
Systemic examination: 
CNS: reflexes- normal
Tone - normal power- 5 in all four limbs  
Sensory system - intact 
Kernigs - terminal rigidity- + (on day 1)
Neck rigidity- present on day 1 
Brudinzkis- absent 
Neck rigidity- resolved by day 2
Kernigs- terminal rigidity - absent by day 2 
CVS: S1 and S2 are heard. No murmurs we’re heard. 
Respiratory system: BAE+ no adventitious sounds were heard 
Per abdominal examination: soft, non-tender and no organomegaly was noted. 
INVESTIGATIONS-









DIAGNOSIS-
PUO WITH RECURRENT FEBRILE SEIZURES
Diagnosed on day 3- ?PERIODIC FEVER SYNDROME (?PFAPA-periodic fever, aphthous stomatitis, pharyngitis, adenitis) WITH RECURRENT ENCEPHALITIS AND IGA NEPHROPATHY ?
TREATMENT-
DAY 1-
IVF-NS, RL
PLENTY OF ORAL FLUIDS
T. DOLO 650MG SOS
INJ.OPTINEURON 1AMP IN 100 ML NS
INJ.CEFTRIAXONE IG IV/BD
T. CEVIPIL 500MG PO/BD
TEMP. CHARTING
GRBS 12TH HRLY
ENT REFERRAL- Done in view of previous h/o rt ear discharge with pain (on and off) since 1 year. 2-3 episodes/yr lasting for 6-7 days. Last episode - 2months back. 
Discharge- mucous, moderate, intermittent, non-foul smelling, non-blood stained.
O/E nose, ear - NORMAL, NO INTERVENTION NEEDED.
Daily routine of the patient 
The patient wakes up everyday at 7:00am. He has breakfast and gets ready to go to college. He travels to his college by bus. He attends his college from 9:00am to 3:00pm. He comes back home by bus. From 4:00pm to 6:00pm he freshens up and takes rest. At 6:00pm he goes to attend Tutions for an hour after which he comes back home and completes his homework. He has dinner at 9:00pm and sleeps at 10:30pm.
The frequent admissions and illness of the patient is subjecting him to mental and academic stress. Mentally, The patient has become more aggressive, stubborn day by day.  Academically he has had a lot of halts. The tuition teacher says his memory is very much hampered. The parents do not know if it’s due to the frequent illness or not. Also, the parents say he tends to get ill during times of stress like exams or something as such.
References-
Inference-
"Periodic fever, Aphthous-stomatitis, Pharyngitis, Adenitis (PFAPA) Syndrome
What is Periodic fever, Aphthous-stomatitis, Pharyngitis, Adenitis (PFAPA) syndrome?
This syndrome includes recurrent episodes of fever with aphthous-stomatitis (mouth sores), pharyngitis (sore throat with redness and sometimes a throat that has a white covering – exudate - like that’s seen in a throat with streptococcal infection). PFAPA affects children in early childhood, usually starting at age 2 to 4 years. Episodes usually decrease in frequency and resolve after the age of 10 years. This disease was recognized for the first time in 1987 and was called Marshall’s.
How common is PFAPA syndrome?
The frequency of PFAPA is not known, but the disease appears to be more common than generally appreciated.
What causes PFAPA syndrome?
The answer to this question is not yet known. No gene defect has been found in PFAPA, although in some cases more than one family member has the disease. No infectious cause has been found in PFAPA, thus it is not a contagious disease. It is clear that the inflammatory process is activated during episodes but it is not clear why it is triggered.
What are the main symptoms of PFAPA syndrome?
The main symptoms of PFAPA are:
Episodic fevers
Sore throat
Mouth ulcers
Enlarged cervical lymph nodes (glands in the neck, an important part of the immune system)
The episodes of fever start abruptly and last for three to seven days. During episodes, the child looks very ill and complains about at least one of the three symptoms mentioned above. The episodes of fever recur every few weeks and often families know the exact day when an attack will start. On the day the fever starts the child will feel a little ill before the attack and the family knows an attack is about to start. Not all children have all symptoms, especially mouth sores. Some children have other symptoms, like:
Joint pain
Abdominal pain
Headache
Vomiting
Diarrhea
How is PFAPA syndrome diagnosed?
There are no laboratory tests, or imaging procedures, specific for diagnosing PFAPA. The disease will be diagnosed based on the results of a physical examination and other symptoms. Inflammatory blood tests like the white blood cell count, erythrocyte sedimentation rate and the C-reactive protein are increased during attacks. Before the diagnosis is confirmed, it is important to exclude all other diseases that may present with similar symptoms (especially a streptococcal throat). The dramatic response to treatment (see below) also helps diagnose PFAPA.
How is PFAPA syndrome treated?
There is no specific treatment to cure PFAPA. The aim of treatment is to control symptoms during the episodes of fever, to shorten the duration of episodes, and in some children to prevent attacks from occurring. In most children, the disease will resolve by itself without treatment, usually after the age of 10 years. The fever does not usually respond well to Tylenol®️ or nonsteroidal anti-inflammatory drugs. A single dose of steroids (usually prednisone), given when symptoms first appear, has been shown to shorten an episode and sometimes even end the episode. However, the interval between episodes may also be shortened with this treatment, and the next episode may occur earlier than expected. In some patients using cimetidine (a medicine that is used to treat stomach ulcers) may prevents attacks from occurring. In patients with very frequent attacks, a tonsillectomy (removing the tonsils by surgery) may be considered.
What is the outcome and course of PFAPA syndrome?
The disease may last for several years. Over time, the intervals between the episodes will increase and usually after the age of 10 years resolve by itself. Children with PFAPA continue to grow and develop normally."
—  PFAPA (Periodic Fever, Aphthous Stomatitis, Pharyngitis, Adenitis) is a childhood syndrome that affects both boys and girls. It causes repeated episodes of fever, mouth sores, sore throat, and swollen lymph nodes. PFAPA usually *starts in early childhood between ages 2 and 5*. In very rare cases, the syndrome may start in adulthood.
DISCHARGE SUMMARY- 
An 18 year old male who is a resident pf Hyderabad and a student presented with the chief complaints of fever since 4 days.  
Vomiting since 4 days.  
Generalised body pains since 4 days. 
Cough without expectoration since 1 day. 
History of presenting illness 
The patient was apparently asymptomatic till the age of 5 years. 
2008 (5years)
2/08/2008: diagnosed and treated for typhoid fever.
17/08/2008: He had high grade fever for two days. On the second day as the fever didn’t subside he was taken to the nursing home. While waiting for the doctor he had an episode of seizure. Due to this he was sent to a nearby hospital where he was treated for the same. 
The seizure lasted for 5 mins. Drugs were given when taken to the hospital following which it subsided. Froth from the mouth was present. No history of bladder and bowel incontinence. Postictal drowsiness was present for 10-15 mins. 
He was admitted in the hospital and discharged after 4 days.
Treatment given: Epsolin (phenytoin) it was continued for 1 week post discharge 
No complaints for the next 3 months. 
1/12/2008 
Complains of cough, abdominal pain, watery discharge from nose 
Sudden onset high grade fever with no chills and rigor since morning. 
1 episode of seizure in the evening for 5 mins. Froth from the mouth was present. No history of bladder and bowel incontinence. Postictal drowsiness and confusion was absent. 
Following which he was admitted in the hospital. 
He had another episode GTCS at 3am for 5 mins. Froth from the mouth was present. No history of bladder and bowel incontinence. Postictal drowsiness was absent. Tongue biting was observed. 
CRP - raised 
EEG - slow activity 
Treatment given: Epsolin (phenytoin), midazolam and diazepam for 5 days. 
Patient was started on sodium valproate 2.5ml BD 
2009  (6 years)
April 2009 
Patient was advised to undergo adeniodectomy and tonsillectomy as it was a underlying cause for febrile seizures. 
7 days post OP 
1 episode of GCTS lasting 1 min followed by 40 mins of postictal drowsiness. Froth from the mouth was present. No history of bladder and bowel incontinence. 
His CRP(1.2mg/dL) and ESR were  raised. 
Treatment: sodium valproate 3ml BD daily. 
2010 (7 years)
June 2010 
1 episode of GTCS lasting for 2 mins. Episode of vomiting during the seizure. Tongue biting was noticed. Froth from the mouth was present. No history of bladder and bowel incontinence. 
CT brain - Normal 
EEG- normal 
Raised ALP:  708U/L
Other LFT were normal 
Sodium valproate serum concentration was observed to be lesser than therapeutic level and thus it’s dosage was increased. 
Treatment: sodium valproate 4ml BD daily 
September 2010 
Patient had abdominal pain for 3 days accompanied with episodes of vomitings and loose motions on the 3rd day 
He was admitted in the hospital 
CBP showed leukocutosis 
LFT showed increased SGOT SGPT and ALP 
Diagnosis given: Anti-epileptic medication induced acute gastritis. 
2012 (9 years)
 April 2012 
Patient had moderate to high grade fever since morning following which he had GTCS lasting for 2 mins. Froth from the mouth was present. No history of bladder and bowel incontinence. Tongue biting was seen. 
He was admitted in the hospital for further evaluation 
His serum sodium valproate concentration was noted to be above therapeutic range. 
He was given Tegretol 7.5 ml BD daily and sodium valproate was stopped. 
2013 (10 years) 
July 2013 
Abdominal pain for 10 days. On day 11th, 1 episode of GTCS lasting 2 mins 
Froth from the mouth was present. No history of bladder and bowel incontinence. No tongue biting was seen. 
EEG was normal 
Tegretol was stopped 
Frisium and Levipril were given for 2 weeks following which levipril was continued. 
No episodes of seizures for 3 years 
2016 (13 years) 
July 2016 
Patient had High grade Fever and multiple episodes of vomiting for 5 days. 
He also had generalised body pain and neck stiffness 
Clinical sings: nystagmus was present. 
Could not walk in a straight line and could not perform Finger nose test. 
CSF analysis: no abnormality
USG ABDOMEN AND PELVIS: B/L enlarged kidneys with grade 1 renal parenchymal changes. Transient proteinuria was present and was treated for the same. 
2017 (14 years)
July 2017 
High grade fever associated with chills and rigor. It was associated with neck pain which radiated to both upper limbs. 
CSF analysis: no abnormality 
MRI: normal 
CRP: raised 
TLC: raised. 
Diagnosis: AFI with encephalitis 
2018 (15years) 
June 2018 
High grade fever on and off since 1 week. 
Cough, throat pain a generalised weakness since 1 week. 
Admitted to hospital for further evaluation. 
TLC: raised 
CRP: raised 
Proteinuria: 2+ 
Diagnosis given: AFI With acute bronchitis. 
2019 (16 years) 
6 years since the last episode of seizures. 
April 2019 
Levipril dose was tapered. 
July 2019 
Patient had high grade fever with chills and rigor. Diagnosed as AFI with sepsis. 
During this fever episode, the dose of Levipril was increased as a prophylaxis to prevent the febrile seizures. It was tapered after the fever subsided. 
August 2019 
1 episode of GTCS lasting 2 mins. Froth from the mouth was present. Postictal confusion for 10 mins. No history of bladder and bowel incontinence. Tongue biting was seen. No history of vomiting. 
LEVIPRIL dose was increased (500mg BD). It is being used till date. 
2021(18 years) 
February 2021 
Increased frequency of micturition for 2 weeks (daytime- 14-15 time night- 4-5 times) frothy urine was observed. 
Cough and cold for 1 week. High grade fever for 5 days. 
Diagnosed with UTI 
Admitted in the hospital and treated for the same. 
24 hour urinary protein was 2488mg/dL
CT abdomen: bulky bilateral renal parenchyma causing partial obliteration of renal sinus fat- likely early pyelonephritis 
Patient was advised a renal biopsy which was not done. 
After discharge the patient was still not relieved of the increased frequency of micturition. 
April 2021 
Ayurvedic medication started for increased frequency of micturition 
May 2021 
Normal frequency of micturition. Ayurvedic medication discontinued. 
H/O Rt ear discharge with pain(on and off) since 1 year. 2-3 episodes/yr lasting for 6-7 days. Last episode - 2months back. 
Discharge- mucous, moderate, intermittent, non-foul smelling, non-blood stained. Treated for the same every time.
The patient was asymptomatic 4 days back when he developed high grade fever which was sudden in onset and varied between a range of 100-104 without touching the baseline. It was associated with chills and rigor 
He has had episodes of vomiting on day 2 and day 4 of symptoms. 
The vomitus contained food particles, it was non bilious and non-projectile. 
He has taken Ayurvedic medication on day 3 of fever for the same.
During the stay- had fever spikes (fever charting above); terminal rigidity and neck rigidity for 2 days; backache for 3 days
Abnormal- 24urinary protein value, RFT, leucocytosis, ESR (elevated).  Reports above ๐Ÿ‘†
DIAGNOSIS- 
Periodic fever since 5 yrs with periodic meningism and glomerular injury.
Treatment in his stay here- 
Day 1-
IVF-NS, RL
PLENTY OF ORAL FLUIDS
T. DOLO 650MG SOS
INJ.OPTINEURON 1AMP IN 100 ML NS
INJ.CEFTRIAXONE IG IV/BD
T. LEVIPIL 500MG PO/BD
TEMP. CHARTING
GRBS 12TH HRLY
Day2-
IVF-NS, RL
PLENTY OF ORAL FLUIDS
T. DOLO 650MG SOS
INJ.OPTINEURON 1AMP IN 100 ML NS
INJ.CEFTRIAXONE IG IV/BD
T. LEVIPIL 500MG PO/BD
TEMP. CHARTING
GRBS 12TH HRLY
Day 3-
IVF-NS, RL
PLENTY OF ORAL FLUIDS
T. DOLO 650MG SOS
INJ.CEFTRIAXONE IG IV/BD
T. LEVIPIL 500MG PO/BD
TEMP. CHARTING
GRBS 12TH HRLY
Day 4-
IVF-NS, RL
PLENTY OF ORAL FLUIDS
T. DOLO 650MG SOS
Stopped antibiotics (ceftriaxone) in v/o negative blood culture and no infective foci
T. LEVIPIL 500MG PO/BD
TEMP. CHARTING
GRBS 12TH HRLY
Day 5-
IVF-NS, RL
PLENTY OF ORAL FLUIDS
T. DOLO 650MG SOS
Stopped antibiotics (ceftriaxone) in v/o negative blood culture and no infective foci
T. LEVIPIL 500MG PO/OD
TEMP. CHARTING
GRBS 12TH HRLY
Advice at discharge- 
Tab. LEVIPIL 500mg OD x 1 week (to taper his dose)
Tab. Pantop 40mg po OD x 5 days
Tab. MVT PO OD x 5 days
REVIEW SOS.
POST DISCHARGE STATUS OF THE PATIENT-
The patient continues to have frothy urine with raised 24hr urinary protein levels.
The patients latest use abdomen shows a normal result in spite of a deranged CT done 10 months back (early pyelonephritis?).
His CUE 
[1.06 pm, 13/11/2025] PPM 1: Today's update:
Good morning
This is the patient’s advocate. I would like to bring to your attention that the patient has been experiencing severe body pain, stiffness, and fever (around 101°F) since Monday. He had taken paracetamol until Tuesday morning, assuming it was due to strain from his journey, as he had traveled to Varanasi and returned on Sunday.
However, since the fever has persisted, we had some basic blood work done, and the CRP level is around 112. As per your previous advice, we have started prednisolone as instructed. 
The first dose of 40 mg was given yesterday at 5 p.m., and the fever came down to normal after about 10 hours, around 4 a.m. this morning. However, the patient continues to experience body pain, stiffness and intermittent severe chills.
 Kindly advise whether to continue the current dosage or if any additional blood tests need to be done.
I guess in the previous episodes too his symptoms came down after a few days of prednisolone 40mg and today is day 2 so it should go by tomorrow perhaps
Please keep sharing his four hourly fever chart.
[1:12 pm, 13/11/2025] PPM 3: Okay sir 
Thankyou
[1:16 pm, 13/11/2025] PPM 1: @PPM3 Please let @CR know if there are any pending updates in the last updated case reports available in the description box and which one should she select for the mirror case report
[1:23 pm, 13/11/2025] PPM 3: Sure sir 
I will do that
[1:46 pm, 13/11/2025] PPM 4: R we sure there's no infection in the current episode?
[2:52 pm, 13/11/2025] PPM 1: Can't be 100 percent sure but it's been recurring in this way since 18-20 years
[5:30 pm, 13/11/2025] PPM 6: Sir, where is this 18 M patient. I want to talk to the advocate
[5:36 pm, 13/11/2025] PPM 4: PFAPA generally responds to single dose prednisolone.
Cimetidine can be tried? Can the LLM search out the evidence around Cimetidine in PFAPA?
[8:15 pm, 13/11/2025] PPM 1: @PPM3 is the advocate
[8:15 pm, 13/11/2025] PPM 1: ๐Ÿ‘†@PPM5
[8:20 pm, 13/11/2025] PPM 5: Yes, cimetidine can be tried for PFAPA syndrome as a prophylactic treatment to reduce the frequency of febrile episodes, though the evidence for its effectiveness is mixed and it is generally not the first-choice therapy .
The table below summarizes the role of cimetidine alongside other common PFAPA treatments for your quick reference.
| *Treatment* | *Type/Purpose* | *Typical Use & Efficacy* | *Key Considerations* |
| :--- | :--- | :--- | :--- |
| *Prednisolone (Prednisone)*  | Abortive (stops attacks) | *Highly effective; stops fever in *~90%* of episodes within hours . | May **shorten interval* between episodes in 25-50% of cases . |
| *Cimetidine*  | Prophylactic (prevents attacks) | *Variable efficacy; some studies show *~40-80%* of patients respond often considered **2nd-line* . | Well-tolerated; *response is unpredictable*; less commonly prescribed in recent years . |
| *Colchicine*  | Prophylactic (prevents attacks) | Considered effective for *reducing attack frequency*; often used when steroids shorten intervals . | Common side effect: gastrointestinal issues (e.g., diarrhea) . |
| *Tonsillectomy*  | Potential cure | Shown to *resolve symptoms in >80%* of children; option for refractory cases . | Invasive; surgical risks; timing is debated . |
### ๐Ÿ”ฌ Evidence and Usage Guidance for Cimetidine
The varied efficacy of cimetidine is reflected in clinical studies and practice:
- *Mixed Research Findings: A 2022 randomized controlled trial found that both cimetidine and colchicine significantly reduced the number of febrile episodes, with **no statistically significant difference in effectiveness between the two drugs* . However, other retrospective studies and reviews note that its efficacy is inconsistent, with some reporting lower response rates .
- *Clinical Usage Trends*: International consensus treatment plans include cimetidine as a prophylactic option, but surveys indicate it is often considered less effective than corticosteroids for aborting attacks or tonsillectomy for potential cure . A 2022 single-center study in Japan deemed cimetidine a suitable initial therapy due to its safety profile.
### ๐Ÿ’ก How to Approach Treatment Decisions
Given the mixed evidence, here's a practical approach to using cimetidine for PFAPA:
- *Consider it for Prophylaxis: Cimetidine is a **preventive medication* taken daily to reduce the frequency of episodes, not for stopping an ongoing attack.
- *Weigh the Options*: Cimetidine may be a reasonable choice if you wish to avoid daily colchicine (due to potential side effects) or the risks of surgery. Its favorable safety profile supports a trial period.
- *Follow Medical Guidance: Diagnosis and treatment should be managed by a pediatric specialist. The 2020 consensus recommends trialing a prophylactic regimen for **three febrile episodes* to assess efficacy before considering a change.
To summarize the evidence for cimetidine in PFAPA:
- *It can be tried* as a prophylactic treatment and is included in international consensus guidelines.
- Its *efficacy is variable* and often less reliable than corticosteroids for acute attacks.
- It is generally considered a *second-line prophylactic option* after evaluating the risks and benefits of corticosteroids and colchicine .
I hope this detailed evidence summary helps you have a more informed discussion with your healthcare provider. For a personalized treatment plan, it is always best to consult with a pediatric rheumatologist or an ENT specialist who has experience with autoinflammatory syndromes.
[8.23 pm, 13/11/2025] PPM 1: ๐Ÿ‘
[10:07 pm, 13/11/2025] PPM 4: Cimetidine is a relatively safe drug, can be tried @PPM1Sir. Atleast its adverse effect profile is better than colchicine
[9.48 pm, 14/11/2025] PPM 3: Good evening sir
Today's update -
He received the third dose of prednisolone at 4 pm today. Notably, the fever has subsided, and there is a marked reduction in body pains and stiffness. Please let us know if the medicine has to be continued for tomorrow also.
[10.20 am, 15/11/2025] PPM 1: Can stop today.
Well done ๐Ÿ‘
Please use two large boxes to enter four hourly data for a single day as demonstrated previously in the same patient's previous graphs shared here ๐Ÿ‘‡
Else yesterday's chart looks as if it has been flattened.
[10.38 am, 15/11/2025] PPM 3: Okay sir
Thankyou.
[6:12 pm, 15/11/2025] PPM 3: Good evening, sir
 Today's update -Temperature remained normal throughout the day with no body pains. I've attached the recent reports for your review.

[7:22 pm, 15/11/2025] PPM 1: Most important tests here would be the fever charting and nothing else is really necessary
[7:31 pm, 15/11/2025] PPM 3: Got it sir
[2:55 pm, 05/02/2026] PPM 1: The patient posted in Narketpally syn group reminded me of the patient here and I also chanced upon this article: https://www.sciencedirect.com/science/article/pii/S1930043325000524
[3:00 pm, 05/02/2026] PPM 1: Also for that patient in the Narketpally group this https://pubmed.ncbi.nlm.nih.gov/36109811/ would be more relevant once we can get his her fever charting and rule out all other causes for his PUO











Monday, October 6, 2025

50M Denovo Hyperglycemia, Seizures Telangana PaJR

 
30-09-2025

THIS IS AN ONLINE E LOG BOOK TO DISCUSS OUR PATIENT'S DE-IDENTIFIED HEALTH DATA SHARED AFTER TAKING HIS SIGNED INFORMED CONSENT. HERE WE DISCUSS PUR PATIENT'S PROBLEMS THROUGH SERIES OF INPUTS FROM AVAILABLE GLOBAL ONLINE COMMUNITY EXPERTS WITH AN AIM TO SOLVE THOSE PATIENT'S CLINICAL PROBLEMS WITH COLLECTIVE CURRENT BEST EVIDENCE BASED INPUTS.

[[30-09-2025 11.36] PPM 1: Initial handwritten history of events
Initial ECG
Another handwritten detail to his smoking history
Handwritten data sheet of assessment and plan
[30-09-2025 11.47] PPM 1: @PPM3 please update his current status whenever you are free
[30-09-2025 14.28] PPM 3: Ok sir
[30-09-2025 16.57] PPM 1: And his SOAP update?
[30-09-2025 17.03] PPM 3: A moment sir
*Subjective complaints*:pain left side of the chest(relatively decreased compared to yesterday)
Fever-1 episode yesterday night
Cough without expectoration 
*Objective*: Tenderness present,at the left side of the chest (patient fell down and injured himself during the seizure episode)
Grbs values:
Yesterday insulin infusion was tapered bridging was done with nph
8AM:216 8 U HAI,4 U NPH
10AM:279
12 PM:216
3 PM:174 8 U HAI 
Assessment:
Pain at left side of chest:chest xray ap view, showing 8,9 rib fracture 
Repeat ecg:as the previous ecg has vpc's 
Today's ecg:??atrial ectopics 
Plan: strapping of chest
continuing antiepileptics, insulin hai+nph subcutaneously 
Started beta blocker:bisoprolol 2.5mg po/od
Inj.augmentin 1.2 gm iv/bd
Syrup ascoryl ls 15 ml po/tid
Uncertainties:
Why HHS?
Why acidosis?
[30-09-2025 20.49] PPM 4: Sir was the MgSO4 administered for hypomagnesaemia or TDP?
Or for its contribution towards the extracellular K+ accumulation?
[30-09-2025 20.54] PPM 1: What could be the possible reasons for this 50M patient with metabolic syndrome phenotype, developing hyperosmolar hyperglycemic state for the first time and how do we explain his acidosis in presence of normal serum creatinine, normal lactate? @Meta AI @PPM5
[30-09-2025 20.54] Meta AI: This is a complex clinical case involving multiple interconnected issues. Here's a breakdown of the uncertainties you raised regarding the patient's presentation:
---
### 1. Why HHS (Hyperosmolar Hyperglycemic State)?
HHS typically occurs in the setting of severe hyperglycemia, dehydration, and insulin deficiency without significant ketosis. Several potential contributing factors for this 50M patient could include:
- *Stress-induced hyperglycemia:* The seizure episode, fall, and trauma (rib fractures) could have led to a significant stress response, causing a surge in counter-regulatory hormones (catecholamines, cortisol, glucagon). This could precipitate HHS in predisposed individuals.
- *Undiagnosed or poorly controlled diabetes:* If this patient has metabolic syndrome, he may have underlying diabetes or impaired glucose tolerance. A triggering event (e.g., infection, trauma, or seizure) might have unmasked or worsened his hyperglycemia.
- *Infection:* Fever and the initiation of antibiotics (augmentin) suggest a possible underlying infection, which is a common precipitant of HHS.
- *Medication-induced hyperglycemia:* If the patient was previously on steroids or other medications that impair glucose tolerance, they could have contributed to the HHS development.
---
### 2. Why Acidosis with Normal Creatinine and Lactate?
The presence of acidosis in HHS is less common but can occur. Possible explanations include:
- *Mixed acid-base disorders:*
    - *Renal tubular acidosis (RTA):* A non-anion gap metabolic acidosis could occur due to tubular dysfunction, even if serum creatinine is normal.
    - *Ketoacidosis:* Mild or early diabetic ketoacidosis (DKA) can coexist with HHS, especially in a patient with metabolic syndrome. This could explain the acidosis despite the absence of significant ketosis (which may not yet be clinically apparent).
    - *Hyperchloremic acidosis:* Rehydration therapy or fluid shifts can cause a non-anion gap metabolic acidosis.
- *Sepsis-related acidosis:* If the patient has an infection (e.g., pneumonia or another source), sepsis could lead to metabolic acidosis despite normal lactate levels early on.
- *Uremia or unmeasured toxins:* Though creatinine is normal, uremia or other toxins (e.g., alcohols, salicylates) might contribute to a high anion gap metabolic acidosis.
---
### Key Considerations for Workup and Management:
1. *Confirm the type of acidosis:*
    - Check arterial blood gas (ABG) to confirm the pH, bicarbonate, and anion gap.
    - Evaluate for ketones (serum/urine) to rule out concomitant DKA.
    - Consider a serum osmolality gap to assess for unmeasured osmoles.
2. *Rule out infection:*
    - Investigate the fever further (e.g., chest imaging, blood cultures) to rule out pneumonia or sepsis.
3. *Monitor and manage HHS:*
    - Ensure adequate hydration, electrolyte correction, and careful insulin titration to avoid rapid shifts in osmolality.
---
What additional labs or findings would you say are most critical to clarify next?
[[30-09-2025 21.01] PPM 1: @PPM6 any idea why we started him on iv magnesium sulphate?
[30-09-2025 21.01] PPM 6: Today morning ECG ..he had atrial bigeminy sir.
[30-09-2025 21.36] PPM 4: This is a complex clinical scenario. The development of a first-time Hyperosmolar Hyperglycemic State (HHS) in a patient with a metabolic syndrome phenotype can be triggered by several factors, and the presence of acidosis despite normal lactate and creatinine levels points toward specific underlying mechanisms.
The table below outlines the most common precipitating factors for a first-time HHS episode.
| Potential Precipitant | Examples & Mechanisms | Relevance to Metabolic Syndrome & First-Time HHS |
| :--- | :--- | :--- |
| **Infection** | Pneumonia, UTI, sepsis. Stress from infection increases counter-regulatory hormones, worsening hyperglycemia. | Most common trigger (50-60% of cases); can unmask previously undiagnosed glucose intolerance. |
| **Certain Medications** | Corticosteroids, thiazide diuretics, some antipsychotics. Can impair carbohydrate metabolism or cause dehydration. | Patients with metabolic syndrome often have conditions (e.g., hypertension) requiring these drugs, increasing risk. |
| **Undiagnosed Type 2 Diabetes** | HHS can be the initial presentation in patients with unknown or poorly managed diabetes. | Metabolic syndrome is a major risk factor for Type 2 Diabetes; HHS may be its first dramatic manifestation. |
| **Cardiovascular Events** | Myocardial infarction, stroke. Physical stress leads to release of stress hormones that spike blood glucose. | Patients with metabolic syndrome have elevated risk for these underlying events. |
| **Inadequate Fluid Intake** | Restricted access to water, impaired thirst, or altered mental status. Reduces the kidney's ability to excrete excess glucose. | Critical co-factor; even without other triggers, poor intake can precipitate HHS in setting of hyperglycemia. |
### ๐Ÿฉบ Explaining the Acidosis with Normal Lactate and Creatinine
The presence of acidosis in HHS, when the classic causes like lactic acidosis (normal lactate) or uremic acidosis (normal creatinine) have been ruled out, can be explained by several other factors:
- **Mild Ketosis**: HHS is defined by the **absence of *significant* ketoacidosis**, but trace to small amounts of ketones may be present. The residual insulin in a patient with metabolic syndrome phenotype is usually enough to suppress ketogenesis, but not always completely. A mild ketosis, combined with a slight elevation in the anion gap, could explain the acidosis without a high lactate level.
- **Hyperchloremic Metabolic Acidosis**: This is a non-anion gap acidosis. During the osmotic diuresis of HHS, patients lose sodium, potassium, and water, but also **chloride** in excess of bicarbonate. This can lead to a normal anion gap metabolic acidosis. Furthermore, as the hyperglycemia is treated with IV fluids, the dilution of serum bicarbonate and the infusion of chloride-containing fluids (e.g., normal saline) can perpetuate or even cause a hyperchloremic acidosis.
- **Other Concurrent Acid-Base Disorders**: The patient might have a mixed disorder. For instance, a mild metabolic acidosis from ketosis could be partially masked by a concurrent metabolic alkalosis caused by factors like vomiting or diuretic use, leading to a confusing overall picture.
To pinpoint the exact cause in this patient, the following diagnostic steps would be crucial:
- **Measure Serum Ketones**: A blood test for **beta-hydroxybutyrate** is more reliable than urine ketones. A level above 3.0 mmol/L suggests diabetic ketoacidosis (DKA), but a mild elevation (e.g., 1.0-3.0 mmol/L) could explain the acidosis in an HHS picture.
- **Analyze the Acid-Base Profile**: Calculate the **anion gap** and compare it with the serum bicarbonate level. This will help distinguish between an anion-gap metabolic acidosis (suggesting ketosis or other unmeasured acids) and a non-anion gap metabolic acidosis (suggesting hyperchloremic acidosis).
- **Review All Medications**: Scrutinize the patient's medication list for any drugs that could cause acidosis or impair kidney function, even if the serum creatinine is currently normal.
I hope this detailed explanation is helpful for your clinical assessment. If you can provide the results of the anion gap and serum ketone tests, a more specific interpretation would be possible.
[30-09-2025 22.34] PPM 1: @PPM3 what was his anion gap?
[30-09-2025 22.36] PPM 5: I couldn't get access to his history as I am new in this group, hope you upload his history again, please
[30-09-2025 22.36] PPM 1: @Meta AI @PPM5 please share a single best RCT on the efficacy of magnesium sulphate improving outcomes in patients with atrial bigeminy and share it's data in a PICO format taking care to avoid percentages and mention absolute values only along with easily searchable references for the same
[30-09-2025 22.36] Meta AI: Currently, there is no high-quality randomized controlled trial (RCT) specifically focused on the efficacy of magnesium sulfate in improving outcomes in patients with atrial bigeminy alone. Most research on magnesium sulfate pertains to its use in broader arrhythmia contexts, such as atrial fibrillation, torsades de pointes, or ventricular arrhythmias. Atrial bigeminy is often a benign condition, and studies tend to focus on broader arrhythmia populations rather than isolating this specific pattern.
That being said, magnesium sulfate is sometimes used empirically in arrhythmia management due to its role in stabilizing cardiac membranes. If you'd like, I can help you find related studies in broader arrhythmia contexts. Would you like me to summarize findings for magnesium sulfate in arrhythmias more generally?
[30-09-2025 22.37] PPM 3: 38 sir on presentation
[30-09-2025 22.37] PPM 1: Very high!  @Meta AI yes
[30-09-2025 22.38] Meta AI: Here’s a summary of findings from studies on magnesium sulfate in broader arrhythmia contexts:
1. *Population*: Patients with various arrhythmias, including atrial fibrillation (AF), ventricular arrhythmias, and torsades de pointes.
2. *Intervention*: Intravenous magnesium sulfate administration.
3. *Comparison*: Placebo or standard antiarrhythmic therapy.
4. *Outcome*: Reduction in arrhythmia episodes, improved rhythm control, and prevention of arrhythmia recurrence.
*Key Evidence*:
- A study by Moran et al. (1995) found magnesium sulfate to be effective in terminating torsades de pointes and preventing recurrence. In patients with AF, magnesium sulfate improved the success rate of cardioversion when used alongside antiarrhythmic drugs.
- In a broader meta-analysis (Shiga et al., 2004), magnesium infusion reduced the incidence of postoperative AF in cardiac surgery patients compared to placebo.
*Absolute Data Example*:
- In postoperative AF prevention, magnesium therapy reduced AF incidence from 33 per 100 patients (placebo) to 18 per 100 patients (magnesium group), showing an absolute reduction of 15 cases per 100 patients.
*Reference*:
- Shiga T, Wajima Z, Inoue T, Ogawa R. Magnesium prophylaxis for arrhythmias after cardiac surgery: a meta-analysis of randomized controlled trials. _Am J Med_. 2004;117(5):325-333. DOI:10.1016/j.amjmed.2004.03.032
Would you like more focused information on a specific arrhythmia or magnesium dosage details?
[30-09-2025 22.39] PPM 1: @Meta AI please share a PICO analysis on a single RCT
[30-09-2025 22.39] Meta AI: Here is a PICO analysis for the *LOMAGHI trial*,¹ a specific RCT investigating magnesium sulfate in atrial fibrillation:
### PICO Analysis:
- *Population*: 450 adult patients with rapid atrial fibrillation (AF) in the emergency department, heart rate >120 bpm, and not candidates for electrical cardioversion. Exclusions included hypotension (SBP <90 mmHg), renal failure, acute MI, CHF (NYHA Class 3/4), or other unstable conditions.
    - Group distribution:
        - High-dose magnesium sulfate (9g): 153 patients
        - Low-dose magnesium sulfate (4.5g): 148 patients
        - Placebo: 149 patients
- *Intervention*: Intravenous magnesium sulfate (either 4.5g or 9g in 100mL normal saline over 30 minutes) as an adjunct to standard rate-control therapy (calcium channel blockers, beta blockers, or digoxin).
- *Comparison*: Placebo (100mL normal saline) with standard AF rate-control therapy.
- *Outcome*:
    - *Therapeutic response rate at 24 hours*:
        - High-dose Mg: 94.1% (144/153 patients)
        - Low-dose Mg: 97.9% (145/148 patients)
        - Placebo: 83.3% (124/149 patients)
   - *Rhythm control (conversion to sinus rhythm at 24 hours)*:
        - High-dose Mg: 13.0% (20/153 patients)
        - Low-dose Mg: 22.9% (34/148 patients)
        - Placebo: 10.7% (16/149 patients)
    - *Resolution time (heart rate <110 bpm)*:
        - High-dose Mg: 5.2 ± 2.0 hours
        - Low-dose Mg: 6.1 ± 1.9 hours
        - Placebo: 8.4 ± 2.5 hours
   - *Adverse effects*:
        - High-dose Mg: 21 total events (18 flushing, 2 hypotension, 1 bradycardia)
        - Low-dose Mg: 8 total events (6 flushing, 1 hypotension, 1 bradycardia)
        - Placebo: 3 total events
### Conclusion:
Low-dose magnesium sulfate (4.5g) was as effective as high-dose (9g) in achieving rate control but had fewer adverse effects. Both magnesium doses outperformed placebo in therapeutic response and rhythm control.
*Reference*:
- Bouida W, et al. "Low-dose magnesium sulfate versus high-dose in early management of rapid atrial fibrillation: Randomized controlled double-blind study." _Acad Emerg Med_, 2018. PMID: 30025177.
Would you like further details about magnesium dosing protocols or other arrhythmia contexts?
[30-09-2025 22.40] PPM 5: I have looked into your request, but the search results do not contain a randomized controlled trial (RCT) that specifically investigates magnesium sulphate for **atrial bigeminy**. The available high-quality studies focus on its use in related conditions like atrial fibrillation.
### ๐ŸŽ“ The Closest Available Evidence
The most relevant RCT identified examines magnesium sulfate for **rapid atrial fibrillation**, which is a different arrhythmia. Here is the data from that study in PICO format:
-   **P** (Population): 199 adult emergency department patients with rapid atrial fibrillation.
-   **I** (Intervention): Intravenous magnesium sulfate (a 2.5 g bolus over 20 minutes, followed by a 2.5 g infusion over 2 hours) in addition to usual care. The most commonly used antiarrhythmic in the usual care group was digoxin.
-   **C** (Comparison): Placebo infusion in addition to usual care.
-   **O** (Outcomes):
    -   **Rate Control**: 63 of 97 patients in the magnesium group achieved a heart rate of less than 100 beats/min, compared to 32 of 93 patients in the placebo group.
    -   **Rhythm Conversion**: 25 of 94 patients in the magnesium group converted to sinus rhythm, compared to 11 of 91 patients in the placebo group.
    -   **Adverse Events**: 14 of 95 patients in the magnesium group experienced an adverse event, compared to 5 of 92 patients in the placebo group.
### ๐Ÿ’ก Why Specific Evidence is Scarce
The lack of direct evidence for atrial bigeminy is likely because:
-   **Clinical Focus is Different**: Atrial bigeminy is often considered a benign rhythm that may not require aggressive intervention unless it is causing significant symptoms. Research efforts are therefore directed toward more consequential arrhythmias like atrial fibrillation or ventricular bigeminy.
-   **Pathophysiology Differs**: The mechanisms that initiate and sustain atrial bigeminy are different from those in atrial fibrillation, so treatment responses may not be comparable.
### ๐Ÿ” How to Find More Information
To continue your search for more targeted evidence, you could:
-   **Consult Specialized Databases**: Search clinicaltrials.gov for any ongoing or completed trials on the topic.
-   **Systematic Search**: Conduct a systematic search on platforms like PubMed or Cochrane Library using a broader search strategy, such as ("magnesium" AND "bigeminy") or ("magnesium" AND "premature atrial complex").
-   **Review Guidelines**: Check clinical practice guidelines from cardiology associations for any mentions of managing frequent atrial ectopy or bigeminy.
I hope this information is helpful for your work. If you have a different clinical scenario in mind, please feel free to ask, and I can search again.
Introduction
Atrial fibrillation (AF) is a prevalent and significant complication following various cardiac procedures, including coronary artery bypass grafting (CABG) and other cardiac surgeries. Its occurrence can lead to increased morbidity and healthcare resource utilization. Given the association between magnesium levels and AF, several studies have explored the efficacy of magnesium sulfate (MgSO4) as a prophylactic or therapeutic agent in preventing and managing AF during the perioperative period. This literature review synthesizes findings from recent randomized controlled trials evaluating the role of magnesium sulfate in the context of atrial arrhythmias, particularly focusing on AF and its implications for clinical practice.
Key Insights
Efficacy of Magnesium Infusion: Continuous infusion of magnesium sulfate has shown effectiveness in reducing the incidence of postoperative atrial fibrillation (POAF). For instance, a study demonstrated a marked reduction in the incidence of POAF in patients undergoing off-pump CABG who received magnesium infusion compared to a control group (19.2% versus 1.9%) 1. This suggests that maintaining adequate magnesium levels can be a critical strategy in preventing AF after cardiac surgery.
Variation in Dosage: Different studies have reported varied outcomes based on the dosage of magnesium administered. One trial investigated the use of low dose versus high dose of magnesium sulfate in patients with rapid AF managed in emergency settings. They found significant therapeutic responses with both dosages, but high doses were associated with more side effects 6. This highlights the need for careful consideration of dosage to balance effectiveness and safety.
Adjunctive Therapy in Rate Control: Magnesium sulfate has been explored as an adjunctive therapy for managing rapid ventricular rates in patients with AF. Randomized controlled trials indicated that magnesium improved heart rate control and increased the likelihood of conversion to sinus rhythm, enhancing the overall management of patients in an emergency department setting 78. However, some studies found no significant difference in AF conversion rates when magnesium was compared to placebo, indicating mixed results regarding its efficacy as a standalone treatment 9.
Postoperative Management: The timing and method of magnesium administration are paramount. A study emphasized the benefit of pre-injection of magnesium sulfate prior to administering antiarrhythmic drugs, which significantly enhanced the efficacy of ibutilide for converting typical atrial flutter 10. This approach could potentially be adapted for broader use in AF management post-surgery.
Safety and Adverse Effects: While magnesium sulfate appears to be effective in reducing AF incidence, concerns regarding safety and potential adverse effects remain. For example, a study found a higher incidence of minor side effects in patients treated with higher doses of magnesium, necessitating a careful approach to supplementation 56.
Conclusion
Magnesium sulfate shows promise as a valuable intervention in the prevention and management of atrial fibrillation, particularly within the postoperative setting of cardiac surgeries. The evidence underscores its role in reducing AF incidence, though the effectiveness may vary with dosage and administration timing. Clinicians must weigh the benefits of magnesium supplementation against the potential for adverse effects. Future research should focus on optimizing administration protocols and exploring the synergistic effects of magnesium with other therapeutic agents to improve patient outcomes related to atrial arrhythmias in the cardiac surgical population. Combining magnesium with other strategies may offer a holistic approach to managing AF, thereby enhancing recovery and minimizing complications after cardiac procedures.
Reference
[1] The Effect of Continuous Magnesium Infusion to Prevent Postoperative Atrial Fibrillation in Patients Undergoing Off-Pump Coronary Artery Bypass Grafting.
[2] Role of del Nido Cardioplegia Solution in Prolonged Aortic Cross-clamp Cardiac Surgery: A Prospective Study.
[3] Magnesium Sulfate: an adjunctive therapy in the first hour of management of rapid atrial fibrillation in the emergency department.
[4] Continuous Magnesium Infusion to Prevent Atrial Fibrillation After Cardiac Surgery: A Sequential Matched Case-Controlled Pilot Study.
[5] Low-dose Magnesium Sulfate Versus High Dose in the Early Management of Rapid Atrial Fibrillation: Randomized Controlled Double-blind Study (LOMAGHI Study).
[6] Magnesium Sulfate Reduces Incidence of Atrial Fibrillation after Coronary Arterial Bypass Surgery: What Is the Proper Dose? A Randomized Trial.
[7] A double-blind randomized clinical trial comparing different doses of magnesium in cardioplegic solution for prevention of atrial fibrillation after coronary artery bypass graft surgery.
[8] Warm-blood cardioplegia with low or high magnesium for coronary bypass surgery: a randomised controlled trial.
[9] Prophylactic intravenous magnesium sulphate in addition to oral {beta}-blockade does not prevent atrial arrhythmias after coronary artery or valvular heart surgery: a randomized, controlled trial.
[10] Role of magnesium in preventing post-operative atrial fibrillation after coronary artery bypass surgery.
[11] Magnesium sulfate versus placebo for paroxysmal atrial fibrillation: a randomized clinical trial.
[12] Pre-injection of magnesium sulfate enhances the efficacy of ibutilide for the conversion of typical but not of atypical persistent atrial flutter.
[13] Impact of magnesium sulfate on serum magnesium concentrations and intracellular electrolyte concentrations among patients undergoing radio frequency catheter ablation.
[14] Effect of single dose magnesium on arrhythmias in patients undergoing coronary artery bypass surgery.
[15] Supplementation of magnesium to warm blood hyperkalemic cardioplegia for the prevention of atrial fibrillation after coronary artery bypass grafting.
[16] Effect of low-dose amiodarone and magnesium combination on atrial fibrillation after coronary artery surgery.
[17] A randomized controlled trial of magnesium sulfate, in addition to usual care, for rate control in atrial fibrillation.
[18] Adjunctive intravenous magnesium to reduce toxicity and enhance efficacy of class III antiarrhythmic agents.
[19] Minimally-diluted blood cardioplegia supplemented with potassium and magnesium for combination of 'initial, continuous and intermittent bolus' administration.
[20] The efficacy of supplemental magnesium in reducing atrial fibrillation after coronary artery bypass grafting.[PubMed ai]
literature-list (2).csv
[02-10-2025 16.15] PPM 3: 1/10/25
[02-10-2025 22.00] PPM 1: Any soap updates?
Yes the case report will be prepared soon.